INDSWFTLTD.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 12:56):

Ind-Swift Limited manufactures and sells pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India...

Stats
Šios dienos apimtis	36 961.00
Vidutinė apimtis	261 278
Rinkos kapitalizacija	1.34B
EPS	INR0 ( 2024-02-14 )
Last Dividend	INR0.400 ( 2011-09-21 )
Next Dividend	INR0 ( N/A )
P/E	4.47
ATR14	INR0.00300 (0.01%)

Tūris Koreliacija

Ilgas: -0.06 (neutral)

Trumpas: 0.00 (neutral)

Signal:(87.188) Neutral

Ind-Swift Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
GUJRAFFIA.NS	0.898
SABTN.NS	0.881
ROLLT.NS	0.876
HYBRIDFIN.NS	0.876
MOREPENLAB.NS	0.874
TGBHOTELS.NS	0.874
21STCENMGM.NS	0.871
MAXIND.NS	0.869
CONFIPET.NS	0.865
NECLIFE.NS	0.865

10 Labiausiai neigiamai susiję koreliacijos
JINDCOT.NS	-0.883
ISMTLTD.NS	-0.861
BLUESTARCO.NS	-0.852
RAJRILTD.NS	-0.844
KAYNES.NS	-0.838
GNA.NS	-0.834
ROTO.NS	-0.827
JINDALSAW.NS	-0.823
DFMFOODS.NS	-0.823
KPRMILL.NS	-0.823

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Ind-Swift Limited Koreliacija - Valiuta/Žaliavos

-0.14
( neutral )

0.22
( neutral )

0.00
( neutral )

-0.60
( weak negative )

-0.09
( neutral )

0.20
( neutral )

Ind-Swift Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR4.11B
Bruto pelnas:	INR1.93B (46.94 %)
EPS:	INR4.81

FY	2022
Pajamos:	INR4.11B
Bruto pelnas:	INR1.93B (46.94 %)
EPS:	INR4.81

FY	2022
Pajamos:	INR3.98B
Bruto pelnas:	INR1.62B (40.63 %)
EPS:	INR-3.70

FY	2021
Pajamos:	INR3.56B
Bruto pelnas:	INR1.70B (47.61 %)
EPS:	INR-5.50

Financial Reports:

No articles found.

Ind-Swift Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Ind-Swift Limited Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0.656 - low (50.00%) | Divividend Growth Potential Score: 2.60 - No dividend growth expected in the near future

Information

First Dividend	INR0.400	2005-09-22
Last Dividend	INR0.400	2011-09-21
Next Dividend	INR0	N/A
Payout Date	2011-10-26
Next Payout Date	N/A
# dividends	7	--
Total Paid Out	INR2.80	--
Avg. Dividend % Per Year	0.00%	--
Score	1.06	--
Div. Sustainability Score	0.656
Div.Growth Potential Score	2.60
Div. Directional Score	1.628	--

Next Divdend (Est)
(2024-06-27)

INR0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

1.06

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR0	0.00%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TATACONSUM.NS	Dividend Junior	2023-05-19	Annually	26	0.60%
NIPPOBATRY.NS	Dividend Junior	2023-09-20	Annually	23	1.06%
INDIANB.NS	Dividend Junior	2023-06-12	Annually	18	1.99%
CIPLA.NS	Dividend Junior	2023-07-20	Annually	28	0.41%
SANGHVIMOV.NS	Dividend Junior	2023-08-04	Sporadic	18	0.41%
M&MFIN.NS	Dividend Junior	2023-07-20	Annually	19	1.20%
GLOBUSSPR.NS	Dividend Junior	2023-07-14	Sporadic	15	0.36%
ASTEC.NS	No Dividend Player	2023-07-20	Annually	15	0.08%
TIPSINDLTD.NS	Dividend Junior	2023-08-03	Annually	17	0.03%
PEL.NS	Dividend Junior	2023-06-16	Annually	29	1.59%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0630	1.500	8.74	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.0420	1.500	-1.578	-2.37	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0.470	1.000	-0.937	-0.937	[3 - 30]
operatingCashFlowPerShareTTM	18.32	2.00	3.89	7.79	[0 - 30]
freeCashFlowPerShareTTM	17.03	2.00	1.487	2.97	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.377	1.000	7.06	7.06	[0.2 - 0.8]
operatingProfitMarginTTM	0.0625	1.000	-0.749	-0.749	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				0.656

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.48	1.000	9.65	0	[1 - 100]
returnOnEquityTTM	-0.0420	2.50	-1.014	-2.37	[0.1 - 1.5]
freeCashFlowPerShareTTM	17.03	2.00	4.32	2.97	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	18.32	2.00	3.89	7.79	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0195	1.500	-3.20	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.210	1.000	7.25	0	[0.1 - 0.5]
Total Score				2.60

Ind-Swift Limited

Ind-Swift Limited manufactures and sells pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrheal, anti-malarial, anti-depressants, cardiology, diabetology, neurology, and oncology. The company also provides contract research and manufacturing services. It serves government dispensaries, doctors, and hospitals through retailers, stockists, and carrying and forwarding channels. The company exports its products to approximately 50 countries. Ind-Swift Limited was founded in 1983 and is based in Chandigarh, India.